よむ、つかう、まなぶ。
【別添】新型コロナウイルス感染症（COVID-19）診療の手引き別冊罹患後症状のマネジメント（第３.０版） (22 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00402.html |
| 出典情報 | 新型コロナウイルス感染症（COVID-19）診療の手引き別冊罹患後症状のマネジメント（第3.0版）（10／20）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
●新型コロナウイルス感染症（COVID-19） 診療の手引き
別冊
罹患後症状のマネジメント・第 3.0 版 ● 2 罹患後症状を訴える患者へのアプローチ
◆引用・参考文献◆
・国際 CFS/ME 学会．筋痛性脳脊髄炎 / 慢性疲労症候群 (ME/CFS) : 臨床医のための手引書．2020． Available from
https://mecfs.ncnp.go.jp/wp/wp-content/uploads/2020/06/4b906f6d9911d2f0d1eb62554ce0cb92.pdf
・日本呼吸器学会．咳嗽に関するガイドライン第 2 版 . 2012 [cited 2012 5/30];
Available from: https://minds.jcqhc.
or.jp/docs/minds/Cough/CPGs2012_Cough.pdf.
・American Academy of Pediatrics. Post-COVID-19 Conditions in Children and Adolescents. 2022 2023-06-12;
Available from: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/
post-covid-19-conditions-in-children-and-adolescents/
・Bowe B, et al. Kidney Outcomes in Long COVID. J Am Soc Nephrol, 2021. 32(11): p. 2851-2862.
・Cardinali DP, et al. Pandi-Perumal, Possible Application of Melatonin in Long COVID. Biomolecules, 2022. 12(11).
・CDC：Post-COVID Conditions: Information for Healthcare Providers.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
・Cdcgov, Post-COVID Conditions: Information for Healthcare Providers. 2023.
・Chiappini E, et al. Recent Insights on Post-COVID in Pediatrics. Pediatr Infect Dis J, 2023.
・COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and
Care Excellence (NICE); 2020 Dec 18.
・D'Ascanio L, et al. Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy
vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results. Eur Rev Med Pharmacol
Sci, 2021. 25(11): p. 4156-4162.
・Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol, 2023. 21(3): p.
133-146.
・England N. Your COVID Recovery/Cough. 2020 2020-06-18; Available from: http://yourcovidrecovery.nhs.uk.
・England N. Your COVID Recovery/Breathlessness. 2020 2020-06-18; Available from: http://yourcovidrecovery.
nhs.uk.
・England, N. Your COVID Recovery/Returning to work. 2022 2022-06-30; Available from: http://
yourcovidrecovery.nhs.uk.
・Horikoshi Y, et al. Post coronavirus disease 2019 condition in children at a children's hospital in Japan. Pediatr
Int, 2023. 65(1): p. e15458.
・Lenze EJ, et al. Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and
Cancer. J Clin Psychiatry, 2023. 84(3).
・Long Covid Symptom Map. Available from: https://www.health.govt.nz/system/files/documents/publications/
hp8627_-_long_covid_symptom_map_v4.pdf. Accessed on June 12, 2023.
・Morioka S, et al. Epidemiology of post-COVID conditions beyond 1 year: a cross-sectional study. Public Health,
2023. 216: p. 39-44.
・National Institute for Health and Care Excellence: Clinical Guidelines, in COVID-19 rapid guideline: managing the
long-term effects of COVID-19. 2020, National Institute for Health and Care Excellence (NICE)Copyright © NICE
2020.: London.
・Sakurada Y, et al. Trends in Long COVID Symptoms in Japanese Teenage Patients. Medicina (Kaunas), 2023.
59(2).
・Salman D, et al. Returning to physical activity after covid-19. Bmj, 2021. 372: p. m4721.
・Sampaio Rocha-Filho, P.A., Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology,
and management. Headache, 2022. 62(6): p. 650-656.
・Takakura K, et al. Clinical features, therapeutic outcomes, and recovery period of long COVID. J Med Virol, 2023.
95(1): p. e28316.
・Tokumasu K, et al. Application of Kampo Medicines for Treatment of General Fatigue Due to Long COVID.
Medicina (Kaunas), 2022. 58(6).
・Tosato M, et al. Effects of l-Arginine Plus Vitamin C Supplementation on Physical Performance, Endothelial
Function, and Persistent Fatigue in Adults with Long COVID: A Single-Blind Randomized Controlled Trial.
Nutrients, 2022. 14(23).
・Vasiliki T, et al. Risk Factors Associated With Post−COVID-19 Condition: A Systematic Review and Meta-analysis.
JAMA Internal Medicine, 2023. 183(6): p. 566-580.
・Vijayakumar B, et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of
individuals with ongoing post-COVID-19 respiratory disease. Immunity, 2022. 55(3): p. 542-556.e5.
・Wright J, et al. The Relationship between Physical Activity and Long COVID: A Cross-Sectional Study. Int J
Environ Res Public Health, 2022. 19(9).
・Xie Y, et al. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern
Med, 2023. 183(6): p. 554-564.
・Xie Y, et al. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol,
2022. 10(5): p. 311-321.
・Xie Y, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med, 2022. 28(3): p. 583-590.
◀︎目次
21
別冊
罹患後症状のマネジメント・第 3.0 版 ● 2 罹患後症状を訴える患者へのアプローチ
◆引用・参考文献◆
・国際 CFS/ME 学会．筋痛性脳脊髄炎 / 慢性疲労症候群 (ME/CFS) : 臨床医のための手引書．2020． Available from
https://mecfs.ncnp.go.jp/wp/wp-content/uploads/2020/06/4b906f6d9911d2f0d1eb62554ce0cb92.pdf
・日本呼吸器学会．咳嗽に関するガイドライン第 2 版 . 2012 [cited 2012 5/30];
Available from: https://minds.jcqhc.
or.jp/docs/minds/Cough/CPGs2012_Cough.pdf.
・American Academy of Pediatrics. Post-COVID-19 Conditions in Children and Adolescents. 2022 2023-06-12;
Available from: https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/
post-covid-19-conditions-in-children-and-adolescents/
・Bowe B, et al. Kidney Outcomes in Long COVID. J Am Soc Nephrol, 2021. 32(11): p. 2851-2862.
・Cardinali DP, et al. Pandi-Perumal, Possible Application of Melatonin in Long COVID. Biomolecules, 2022. 12(11).
・CDC：Post-COVID Conditions: Information for Healthcare Providers.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html
・Cdcgov, Post-COVID Conditions: Information for Healthcare Providers. 2023.
・Chiappini E, et al. Recent Insights on Post-COVID in Pediatrics. Pediatr Infect Dis J, 2023.
・COVID-19 rapid guideline: managing the long-term effects of COVID-19. London: National Institute for Health and
Care Excellence (NICE); 2020 Dec 18.
・D'Ascanio L, et al. Randomized clinical trial "olfactory dysfunction after COVID-19: olfactory rehabilitation therapy
vs. intervention treatment with Palmitoylethanolamide and Luteolin": preliminary results. Eur Rev Med Pharmacol
Sci, 2021. 25(11): p. 4156-4162.
・Davis HE, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol, 2023. 21(3): p.
133-146.
・England N. Your COVID Recovery/Cough. 2020 2020-06-18; Available from: http://yourcovidrecovery.nhs.uk.
・England N. Your COVID Recovery/Breathlessness. 2020 2020-06-18; Available from: http://yourcovidrecovery.
nhs.uk.
・England, N. Your COVID Recovery/Returning to work. 2022 2022-06-30; Available from: http://
yourcovidrecovery.nhs.uk.
・Horikoshi Y, et al. Post coronavirus disease 2019 condition in children at a children's hospital in Japan. Pediatr
Int, 2023. 65(1): p. e15458.
・Lenze EJ, et al. Beyond "Psychotropic": Repurposing Psychiatric Drugs for COVID-19, Alzheimer's Disease, and
Cancer. J Clin Psychiatry, 2023. 84(3).
・Long Covid Symptom Map. Available from: https://www.health.govt.nz/system/files/documents/publications/
hp8627_-_long_covid_symptom_map_v4.pdf. Accessed on June 12, 2023.
・Morioka S, et al. Epidemiology of post-COVID conditions beyond 1 year: a cross-sectional study. Public Health,
2023. 216: p. 39-44.
・National Institute for Health and Care Excellence: Clinical Guidelines, in COVID-19 rapid guideline: managing the
long-term effects of COVID-19. 2020, National Institute for Health and Care Excellence (NICE)Copyright © NICE
2020.: London.
・Sakurada Y, et al. Trends in Long COVID Symptoms in Japanese Teenage Patients. Medicina (Kaunas), 2023.
59(2).
・Salman D, et al. Returning to physical activity after covid-19. Bmj, 2021. 372: p. m4721.
・Sampaio Rocha-Filho, P.A., Headache associated with COVID-19: Epidemiology, characteristics, pathophysiology,
and management. Headache, 2022. 62(6): p. 650-656.
・Takakura K, et al. Clinical features, therapeutic outcomes, and recovery period of long COVID. J Med Virol, 2023.
95(1): p. e28316.
・Tokumasu K, et al. Application of Kampo Medicines for Treatment of General Fatigue Due to Long COVID.
Medicina (Kaunas), 2022. 58(6).
・Tosato M, et al. Effects of l-Arginine Plus Vitamin C Supplementation on Physical Performance, Endothelial
Function, and Persistent Fatigue in Adults with Long COVID: A Single-Blind Randomized Controlled Trial.
Nutrients, 2022. 14(23).
・Vasiliki T, et al. Risk Factors Associated With Post−COVID-19 Condition: A Systematic Review and Meta-analysis.
JAMA Internal Medicine, 2023. 183(6): p. 566-580.
・Vijayakumar B, et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of
individuals with ongoing post-COVID-19 respiratory disease. Immunity, 2022. 55(3): p. 542-556.e5.
・Wright J, et al. The Relationship between Physical Activity and Long COVID: A Cross-Sectional Study. Int J
Environ Res Public Health, 2022. 19(9).
・Xie Y, et al. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. JAMA Intern
Med, 2023. 183(6): p. 554-564.
・Xie Y, et al. Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol,
2022. 10(5): p. 311-321.
・Xie Y, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med, 2022. 28(3): p. 583-590.
◀︎目次
21